€15 million to advance clinical single cell profiling
One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities.
The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences’ total funding to date to over €20 million, including Home Biosciences’ seed financing.
One Biosciences technology creates detailed functional profiles of patient tumours, unlocking insights that may drive better clinical decision-making, patient selection, therapy development, and potentially optimising clinical trials. Proceeds from the financing will accelerate the clinical development of One Biosciences’ OneMap platform and support the scaling of strategic partnerships with pharmaceutical and biotech companies.
Hedi Ben Brahim, CEO of One Biosciences, said: “This funding enables us to translateour breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market.”
Dr Céline Vallot, Co-Founder of One Biosciences and Group Leader at Curie Institute, commented: “This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical grade specimens.”
Dr Mehdi Touat, Assistant Professor, Assistance Publique – Hôpitaux de Paris AP-HP, Pitié-Salpêtrière and Paris Brain Institute, said: “Widespread use of next generation sequencing (NGS) profiling has led to substantial advances in cancer care but the clinical benefit remains limited to small patient subsets. We believe clinical grade single cell profiling has the potential to catalyse the next generation of diagnostic and therapeutic advances.”
Megan Thomas, Multimedia Editor, DDW